Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 435

1.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print]

PMID:
30283029
2.

Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression.

Ulke C, Tenke CE, Kayser J, Sander C, Böttger D, Wong LYX, Alvarenga JE, Fava M, McGrath PJ, Deldin PJ, Mcinnis MG, Trivedi MH, Weissman MM, Pizzagalli DA, Hegerl U, Bruder GE.

Clin EEG Neurosci. 2018 Sep 5:1550059418795578. doi: 10.1177/1550059418795578. [Epub ahead of print]

PMID:
30182751
3.

Toward a very brief quality of life enjoyment and Satisfaction Questionnaire.

Rush AJ, South CC, Jha MK, Grannemann BD, Trivedi MH.

J Affect Disord. 2019 Jan 1;242:87-95. doi: 10.1016/j.jad.2018.08.052. Epub 2018 Aug 15.

PMID:
30173063
4.

Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Jha MK, Trivedi MH.

Focus (Am Psychiatr Publ). 2018 Jul;16(3):279-284. doi: 10.1176/appi.focus.20180013. Epub 2018 Jul 18. No abstract available.

PMID:
30147629
5.

Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.

Jha MK, Malchow AL, Grannemann BD, Rush AJ, Trivedi MH.

Neuropsychopharmacology. 2018 Oct;43(11):2197-2203. doi: 10.1038/s41386-018-0180-z. Epub 2018 Aug 15.

PMID:
30135556
6.

Development and evaluation of a multimodal marker of major depressive disorder.

Yang J, Zhang M, Ahn H, Zhang Q, Jin TB, Li I, Nemesure M, Joshi N, Jiang H, Miller JM, Ogden RT, Petkova E, Milak MS, Sublette ME, Sullivan GM, Trivedi MH, Weissman M, McGrath PJ, Fava M, Kurian BT, Pizzagalli DA, Cooper CM, McInnis M, Oquendo MA, Mann JJ, Parsey RV, DeLorenzo C.

Hum Brain Mapp. 2018 Nov;39(11):4420-4439. doi: 10.1002/hbm.24282. Epub 2018 Aug 16.

PMID:
30113112
7.

A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial.

Trivedi MH, South C, Jha MK, Rush AJ, Cao J, Kurian B, Phillips M, Pizzagalli DA, Trombello JM, Oquendo MA, Cooper C, Dillon DG, Webb C, Grannemann BD, Bruder G, McGrath PJ, Parsey R, Weissman M, Fava M.

Psychother Psychosom. 2018;87(5):285-295. doi: 10.1159/000491093. Epub 2018 Aug 15.

PMID:
30110685
8.

The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.

Rethorst CD, Hamann HA, Carmody TJ, Sharp KJ, Argenbright KE, Haley BB, Skinner CS, Trivedi MH.

BMC Cancer. 2018 Jul 18;18(1):744. doi: 10.1186/s12885-018-4662-5.

9.

Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.

Gadad BS, Raj P, Jha MK, Carmody T, Dozmorov I, Mayes TL, Wakeland EK, Trivedi MH.

Mol Neuropsychiatry. 2018 Jun;4(1):7-19. doi: 10.1159/000487321. Epub 2018 May 3.

10.

Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program.

Kahalnik F, Sanchez K, Faria A, Grannemann B, Jha M, Tovian C, Clark EW, Levinson S, Pipes R, Pederson M, Trivedi MH.

Int J Qual Health Care. 2018 Jul 4. doi: 10.1093/intqhc/mzy128. [Epub ahead of print]

PMID:
29982702
11.

Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

Webb CA, Trivedi MH, Cohen ZD, Dillon DG, Fournier JC, Goer F, Fava M, McGrath PJ, Weissman M, Parsey R, Adams P, Trombello JM, Cooper C, Deldin P, Oquendo MA, McInnis MG, Huys Q, Bruder G, Kurian BT, Jha M, DeRubeis RJ, Pizzagalli DA.

Psychol Med. 2018 Jul 2:1-10. doi: 10.1017/S0033291718001708. [Epub ahead of print]

PMID:
29962359
12.

Statistical harmonization corrects site effects in functional connectivity measurements from multi-site fMRI data.

Yu M, Linn KA, Cook PA, Phillips ML, McInnis M, Fava M, Trivedi MH, Weissman MM, Shinohara RT, Sheline YI.

Hum Brain Mapp. 2018 Nov;39(11):4213-4227. doi: 10.1002/hbm.24241. Epub 2018 Jul 1.

PMID:
29962049
13.

Association of Midlife Cardiorespiratory Fitness With Incident Depression and Cardiovascular Death After Depression in Later Life.

Willis BL, Leonard D, Barlow CE, Martin SB, DeFina LF, Trivedi MH.

JAMA Psychiatry. 2018 Sep 1;75(9):911-917. doi: 10.1001/jamapsychiatry.2018.1467.

PMID:
29955781
14.

Association of T and non-T cell cytokines with anhedonia: Role of gender differences.

Jha MK, Miller AH, Minhajuddin A, Trivedi MH.

Psychoneuroendocrinology. 2018 Sep;95:1-7. doi: 10.1016/j.psyneuen.2018.05.017. Epub 2018 May 12.

PMID:
29783087
15.

Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study.

Trombello JM, Pizzagalli DA, Weissman MM, Grannemann BD, Cooper CM, Greer TL, Malchow AL, Jha MK, Carmody TJ, Kurian BT, Webb CA, Dillon DG, McGrath PJ, Bruder G, Fava M, Parsey RV, McInnis MG, Adams P, Trivedi MH.

J Psychiatr Res. 2018 Jul;102:207-215. doi: 10.1016/j.jpsychires.2018.04.003. Epub 2018 Apr 6.

PMID:
29689518
16.

A Complier Average Causal Effect Analysis of the Stimulant Reduction Intervention using Dosed Exercise Study.

Carmody T, Greer TL, Walker R, Rethorst CD, Trivedi MH.

Contemp Clin Trials Commun. 2018 Jun;10:1-8. doi: 10.1016/j.conctc.2018.02.001.

17.

Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality.

Mayes TL, Kennard BD, Killian M, Carmody T, Grannemann BD, Rush AJ, Jha MK, Hughes J, Emslie GJ, Trivedi MH.

J Affect Disord. 2018 Aug 1;235:45-51. doi: 10.1016/j.jad.2018.03.007. Epub 2018 Mar 26. Review.

PMID:
29649710
18.

Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial.

Pizzagalli DA, Webb CA, Dillon DG, Tenke CE, Kayser J, Goer F, Fava M, McGrath P, Weissman M, Parsey R, Adams P, Trombello J, Cooper C, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G, Trivedi MH.

JAMA Psychiatry. 2018 Jun 1;75(6):547-554. doi: 10.1001/jamapsychiatry.2018.0252.

PMID:
29641834
19.

A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder.

Sanchez K, Killian MO, Mayes TL, Greer TL, Trombello JM, Lindblad R, Grannemann BD, Carmody TJ, Rush AJ, Walker R, Trivedi MH.

J Psychiatr Res. 2018 Jul;102:65-71. doi: 10.1016/j.jpsychires.2018.03.012. Epub 2018 Mar 27.

PMID:
29626753
20.

Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.

Jha MK, Wakhlu S, Dronamraju N, Minhajuddin A, Greer TL, Trivedi MH.

J Affect Disord. 2018 Jul;234:34-37. doi: 10.1016/j.jad.2018.02.089. Epub 2018 Feb 27.

PMID:
29522941

Supplemental Content

Loading ...
Support Center